Fig. 2From: Evaluating the clinical significance of SHMT2 and its co-expressed gene in human kidney cancerAssociation between SHMT2 gene expression and clinical pathological parameters in patients with renal clear cell carcinoma (UALCAN). a expression of SHMT2 in normal and renal clear cell carcinoma tissues based on patients’ age; b expression of SHMT2 in normal and renal clear cell carcinoma tissues based on cancer stages; c expression of SHMT2 in normal and renal clear cell carcinoma tissues based on patients’ gender; d expression of SHMT2 in normal and renal clear cell carcinoma tissues based on patients’ race; e expression of SHMT2 in normal and renal clear cell carcinoma tissues based on tumor grade. #P:compared to normal group; &P: compared to the age (21–40 years) group; $P: compared to the Stage 2 group; *P: compared to the Caucasian groupBack to article page